慢性乙型肝炎和乙肝肝硬化应用艾米替诺福韦片联合护肝胶囊治疗的疗效分析  

Analysis of the Efficacy of Chronic Hepatitis B and Hepatitis B Cirrhosis Treated with the Application of Tenofovir Amibufenamide Tablets Combined with Liver Protection Capsules

作　　者：钱卫[1] 顾宇峰[2] QIAN Wei;GU Yufeng(Department of Infection,Yancheng Third People′s Hospital,Yancheng,Jiangsu Province,224001 China;Department of Infectious Diseases,Affiliated Hospital of Nantong University,Nantong,Jiangsu Province,226001 China)

机构地区：[1]盐城市第三人民医院感染科,江苏盐城224001 [2]南通大学附属医院感染性疾病科,江苏南通226001

出　　处：《系统医学》2023年第16期83-86,共4页Systems Medicine

摘　　要：目的分析艾米替诺福韦片联合护肝胶囊在治疗慢性乙型肝炎和乙肝肝硬化中的效果。方法选取2021年9月—2023年3月盐城市第三人民医院收治的128例慢性乙型肝炎和乙肝肝硬化患者为研究对象,按照治疗方案差异进行组别划分,对照组64例艾米替诺福韦片治疗,观察组64例在对照组基础上联合护肝胶囊治疗,对比两组患者治疗效果、乙型肝炎表面抗原、谷丙转氨酶、乙肝病毒基因、肝脏硬度及治疗不良反应发生情况。结果两组患者治疗总有效率比较,观察组96.88%高于对照组87.50%,差异有统计学意义(χ^(2)=3.905,P<0.05);治疗后12、24、36、48周时间点,观察组乙型肝炎表面抗原(hepatitis B surface antigen,HBsAg)、谷丙转氨酶(alanine transaminase,ALT)、乙肝病毒基因(hepatitis B virus deoxyribonucleic acid,HBVDNA)、肝脏硬度均明显低于对照组,差异有统计学意义(P<0.05);同组患者的HBsAg、ALT、HBV DNA、肝脏硬度在治疗后12、24、36、48周和治疗前比较,差异有统计学意义(P<0.05);两组患者不良反应情况比较,差异无统计学意义(P>0.05)。结论艾米替诺福韦片联合护肝胶囊在治疗慢性乙型肝炎、乙肝肝硬化中体现出明显临床优势,对肝功能起到明显的改善,有效抑制病情进展,符合患者的治疗需求。Objective To analyze the effect of tenofovir amibufenamide tablets combined with liver protection capsule in the treatment of chronic hepatitis B and hepatitis B cirrhosis.Methods 128 patients with chronic hepatitis B and hepatitis B cirrhosis diagnosed and treated by Yancheng Third People′s Hospital during September 2021-March 2023 were selected as study subjects,and the groups were divided according to the differences in treatment regimens.In the control group,64 cases were treated with tenofovir amibufenamide tablets,and in the observation group,64 cases were treated with liver protection capsules on the basis of the control group.Comparison of the treatment effect,hepatitis B surface antigen,glutamic transaminase,hepatitis B viral gene,liver hardness and adverse reactions to treatment between the two groups.Results Comparing the total effective rate of treatment between the two groups,96.88%of the observation group was higher than 87.50%of the control group,and the difference was statistically significant(χ^(2)=3.905,P<0.05).At the time points of 12,24,36,and 48 weeks after treatment,the hepatitis B surface antigen(HBsAg),alanine transaminase(ALT),hepatitis B virus deoxyribonucleic acid(HBV-DNA),and liver hardness were significantly lower in the observation group than in the control group,and the difference was statistically significant(P<0.05).Comparison of HBsAg,ALT,HBV-DNA,and liver hardness in the same group was statistically significant at 12,24,36,and 48 weeks after treatment and before treatment(P<0.05).There was no statistically significant comparison of the adverse reaction profile between the two groups(P>0.05).Conclusion Tenofovir amibufenamide tablets combined with liver protection capsule in the treatment of chronic hepatitis B,hepatitis B cirrhosis reflects obvious clinical advantages,plays an obvious improvement in liver function,effectively inhibit the progress of the disease,in line with the treatment needs of patients.

关 键 词：慢性乙型肝炎 乙肝肝硬化 艾米替诺福韦片 护肝胶囊 安全性 

分 类 号：R512[医药卫生—内科学]